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MEASURING THE COST OF ILLNESS RELATED ALCOHOL IN KOREA
Ko S, Jung YH
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVES: Excessive consumption of alcohol could cause severe adverse conse-
quences. This study aims at measuring the costs of illness related alcohol in Korea. 
METHODS: This study employs a prevalence-based approach. First, we review the 
existing literature for selecting alcohol-related diseases, then estimate both direct and 
indirect costs of the selected diseases. Next, we compute population attributable risks 
(PARs) at the risk levels (high- and very high-risk) by daily volume. Finally, the esti-
mated socioeconomic costs of illness related alcohol are derived by multiplying the 
costs of alcohol-related diseases by PARs. Direct costs include medical care expendi-
tures, caregiver’s costs, and trafﬁ c costs. Indirect costs are estimated based on human 
capital theory. The estimated costs are categorized by age of 20 and higher, sex, 
diseases at the corresponding risk levels. Further, lost earnings due to premature death 
caused by drink driving fatalities are also estimated based on human capital theory. 
The cost estimates are reported in US Purchasing Power Parity Dollars. The major 
data sources are National Health Insurance Statistical Yearbook, Annual Report on 
the Cause of Death Statistics, Survey Report on Wage Structure, National Health and 
Nutrition Survey, the Korean Statistical Information System among others. RESULTS: 
The estimated socioeconomic cost of illness due to alcohol in Korea in 2007 is 6,709 
million PPP$ at 0% discount rate. The costs of the high risk group and the very high 
risk are 2121 million PPP$ and 4588 million PPP $ respectively. The cost of male 
(6416 million PPP$) is about 22 times of the cost of female (293 million PPP$). In 
addition, we get 493 million PPP$ for lost earnings due to premature death caused by 
fatal trafﬁ c accidents. CONCLUSIONS: Excessive consumption of alcohol incurs 
external costs as well as internal cost, which could give us a rationale for intervention. 
We need to develop our capacity for controlling consumption of alcohol. 
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FACTORS ASSOCIATED WITH TOTAL TIME AND COST OF PROVIDING 
CARE FOR THAI PATIENTS WITH DEMENTIA
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OBJECTIVES: To examine factors associated with total time and cost of providing 
care for patients with dementia in outpatient clinics at a university hospital in 
Bangkok. METHODS: Primary caregivers for patients with dementia diagnosed with 
probable Alzheimer’s disease or vascular dementia and receiving medical care from 
outpatient clinics were selected. Data were collected from primary caregivers using 
questionnaires during February 1–July 31, 2007. Dependent variable was total time 
or total cost of providing care by family members without ﬁ nancial compensation 
(informal care) or other caregivers with ﬁ nancial compensation (formal care). Inde-
pendent variables were demographic factors of primary caregivers (e.g., age, gender, 
education, and occupation), relationship with patients, and disease severity of patients. 
Univariate and multivariate statistical analyses were applied. RESULTS: Informal care 
cost accounted for 82% of total cost of providing care. Patients with moderate to 
severe (parameter estimate, PE = 0.897, P < 0.002) or severe dementia (PE = 1.785; 
P < 0.001) needed signiﬁ cantly longer time of care compared to those with mild 
dementia. Patient’s spouse provided less time of taking care compared to hired caregiv-
ers or patient’s child (PE = −1.159, P < 0.001). In addition, patients with severe 
dementia signiﬁ cantly consumed higher cost of providing care compared to those with 
mild or moderate to severe dementia (PE = 1.611, P < 0.001). Primary caregivers with 
bachelor degree or higher (PE = 1.054, P < 0.007) or receiving ﬁ nancial compensation 
(PE = 0.901, P < 0.045) signiﬁ cantly increased the total cost of providing care. The 
models investigating the factors associated with total time or cost of providing care 
could explain approximately 41% or 31%, respectively. CONCLUSIONS: Informal 
care cost can lead to a signiﬁ cant economic burden to the families of patients with 
dementia in Thailand. Factors associated with total time and cost of providing care 
may help develop the health-care system of providing care for patients with dementia 
in the future. 
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OBJECTIVES: To compare health-care resource utilization costs and cost components 
for newly diagnosed schizophrenia patients who were initiated on olanzapine or ris-
peridone monotherapy in Japan. METHODS: Medical claim data were extracted from 
the Japan Medical Data Centre database for subjects who were: 1) at least 20 years 
old; 2) having a new medical claim with a ICD-10 diagnostic code representing 
schizophrenia and related disorders, issued in August 2004 through October 2006; 3) 
having no medical claim with schizophrenia-related diagnostic codes during the year 
before the most recent medical claim; and 4) no prior administration of antipsychotic 
drugs. The olanzapine and risperidone-initiated subjects were compared on total direct 
health-care utilization costs and cost components such as antipsychotic medication 
costs and costs of anticholinergic agents during the 3 and 12 months following treat-
ment initiation. RESULTS: Following 3 months of treatment, the olanzapine group 
(n = 158) incurred signiﬁ cantly lower total direct cost compared to the risperidone 
group (n = 225) ($1142 vs. $1661, respectively, P = 0.042). The total 12-months direct 
cost was numerically but not statistically signiﬁ cantly lower for the olanzapine com-
pared to the risperidone-initiated group ($2898 vs. $3669, Student’s t-test, P = 0.165). 
The antipsychotic medication acquisition cost was signiﬁ cantly higher for the olan-
zapine ($421) compared with the risperidone group ($244) (P = 0.002), whereas the 
cost of anticholinergic agents was higher for the risperidone ($8.5) compared to the 
olanzapine group ($4.7, P = 0.384). CONCLUSIONS: This retrospective claim data-
base analysis of Japanese data for persons newly diagnosed with schizophrenia and 
related disorders estimated that olanzapine is economically more advantageous than 
risperidone in the early phase of treatment (ﬁ rst 3 months), whereas the total annual 
expenditures appear to not statistically signiﬁ cantly differ between the olanzapine and 
risperidone-initiated monotherapy groups. 
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CHARACTERISTICS OF OUTPATIENTS INITIATED ON OLANZAPINE 
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OBJECTIVES: To compare the characteristics of outpatients who were initiated on 
olanzapine versus risperidone in the naturalistic treatment of schizophrenia in Japan. 
METHODS: The Japan Medical Data Centre Database was used to identify patients 
diagnosed with schizophrenia or schizoaffective disorder, per ICD-10 codes. Patients 
had to be 20–65 years old, to have initiated olanzapine or risperidone therapy at any 
outpatient setting between January 2004 and July 2008 and to be continuously 
enrolled during the 6 months prior and 12 months post initiation date. Initiation was 
deﬁ ned as the ﬁ rst prescription of olanzapine or risperidone (index drug) that was 
preceded by 3 months without a prescription for that index drug. Treatment groups 
were compared on demographics, medical and psychiatric comorbidities, prior medi-
cation use patterns and prior resource utilization (6 months prior to initiation). Chi-
square tests and t-tests were employed for group comparisons. RESULTS: Compared 
to patients initiated on risperidone (n = 502), the olanzapine-initiated patients (n = 
334) were signiﬁ cantly more likely to be previously diagnosed with a mood disorder 
(59.3% vs. 51.6%, P < 0.05) and be treated with antidepressants (56.6% vs. 43.8%, 
P < 0.05). The olanzapine-treated group was also signiﬁ cantly less likely to be previ-
ously use adjunctive anticholinergics (20.7% vs. 27.3%, P < 0.05). The treatment 
groups did not signiﬁ cantly differ on demographics, on prior hospitalization rates or 
duration, number of outpatient visits, use of typical or atypical antipsychotics, and 
use of antipsychotic polypharmacy. CONCLUSIONS: Current ﬁ ndings suggest that 
in Japan, olanzapine was used more often for patients with comorbid mood disorders 
and use of antidepressants. Prior research has shown that schizophrenia patients with 
comorbid depressive symptoms are of greater safety concern (e.g., suicidal, violent) 
and show poorer medication adherence. 
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OBJECTIVES: Sertindole is an atypical antipsychotic medication in schizophrenia. It 
has a good tolerability proﬁ le likely to favor long-term adherence, reductions in relapse 
and re-hospitalization rates, and improvements in quality of life. This study assessed 
the cost effectiveness of antipsychotics in South Korean setting. METHODS: A 
Markov model was developed to estimate the cost-effectiveness of sertindole compared 
with risperidone, olanzapine and quetiapine in the management of chronic schizophre-
nia over a 5-year period. Patients entered the model upon experiencing intolerance to 
their antipsychotic treatment during an episode of acute psychopathology. Confound-
ing factors included drug-induced adverse events (extrapyramidal symptoms, weight 
gain, sedation, sexual dysfunction and diabetes), compliance, relapse and treatment 
in hospital setting. Effectiveness was deﬁ ned as the length of time without relapse over 
the evaluation period, and by Quality-Adjusted Life-years (QALYs). Parameter esti-
mates were based upon published literature and clinical trial data. Resource utilization 
data were obtained from the 2009 National Health Insurance Reimbursement Data 
and costs were estimated from the social perspective. RESULTS: The time without 
relapse (over ﬁ ve-year) for patients receiving sertindole was similar to those with 
risperidone, olanzapine and quetiapine (1.9030 vs. 1.9025, 1.9025 and 1.9028). Per 
patient costs over 5-year with sertindole was below that of olanzapine (KRW 10.5M 
vs. 12.9M) but above the costs of risperidone and quetiapine (KRW 10.5M vs. 8.4M 
and 8.9M). Based on the outcome of the model, the effectiveness of sertindole is almost 
equivalent to that of the other atypical antipsychotics. But medical costs (including 
in- and outpatient care) for sertindole are similar to or marginally higher than those 
of the other atypical antipsychotics. CONCLUSIONS: Though not cost-effective, but 
with equivalent clinical effectiveness, a good tolerability proﬁ le and acceptable costs, 
sertindole is an additional valuable treatment alternative to other atypical antipsychot-
ics in South Korea. 
